Adamis Pharmaceuticals Corporation [NASDAQ: ADMP] closed the trading session at $0.73 on 01/12/21. The day’s price range saw the stock hit a low of $0.691, while the highest price level was $0.794. The company report on December 1, 2020 that Adamis Pharmaceuticals Describes Planned Response to ZIMHI Complete Response Letter.
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced a planned response to a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA), regarding its New Drug Application (NDA) for Adamis’ ZIMHI™ high dose naloxone injection product for the treatment of opioid overdose.
The CRL, received November 13, 2020, identified deficiencies that the FDA determined must be corrected before the Agency can approve the NDA, and provided recommendations needed for resubmission. FDA had not previously identified those deficiencies. Adamis intends to address all the deficiencies raised in the CRL and request that FDA approve the NDA. All of the company’s responses to the deficiencies will be submitted before year end. The company will then ask the FDA for a Type A meeting. If the matter cannot be resolved with the FDA Division that sent the CRL, Adamis intends to appeal the matter within the agency through a Formal Dispute Resolution.
The stocks have a year to date performance of 50.48 percent and weekly performance of 18.66 percent. The stock has been moved at 19.46 percent over the last six months. The stock has performed 32.73 percent around the most recent 30 days and changed -27.72 percent over the most recent 3-months.
If compared to the average trading volume of 5.24M shares, ADMP reached to a volume of 12740817 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Adamis Pharmaceuticals Corporation [ADMP]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ADMP shares is $1.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ADMP stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Maxim Group have made an estimate for Adamis Pharmaceuticals Corporation shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 13, 2020. The new note on the price target was released on February 27, 2020, representing the official price target for Adamis Pharmaceuticals Corporation stock. On July 16, 2019, analysts decreased their price target for ADMP shares from 1.90 to 1.10.
The Average True Range (ATR) for Adamis Pharmaceuticals Corporation is set at 0.06, with the Price to Sales ratio for ADMP stock in the period of the last 12 months amounting to 3.76. The Price to Book ratio for the last quarter was 2.03, with the Price to Cash per share for the same quarter was set at 0.13.
ADMP stock trade performance evaluation
Adamis Pharmaceuticals Corporation [ADMP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 18.66. With this latest performance, ADMP shares gained by 32.73% in over the last four-week period, additionally plugging by 19.46% over the last 6 months – not to mention a drop of -4.82% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADMP stock in for the last two-week period is set at 73.00, with the RSI for the last a single of trading hit 81.87, and the three-weeks RSI is set at 65.18 for Adamis Pharmaceuticals Corporation [ADMP]. The present Moving Average for the last 50 days of trading for this stock 0.5544, while it was recorded at 0.6996 for the last single week of trading, and 0.6551 for the last 200 days.
Adamis Pharmaceuticals Corporation [ADMP]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Adamis Pharmaceuticals Corporation [ADMP] shares currently have an operating margin of -135.67 and a Gross Margin at +17.80. Adamis Pharmaceuticals Corporation’s Net Margin is presently recorded at -132.53.
Return on Total Capital for ADMP is now -67.13, given the latest momentum, and Return on Invested Capital for the company is -69.60. Return on Equity for this stock declined to -70.85, with Return on Assets sitting at -54.46. When it comes to the capital structure of this company, Adamis Pharmaceuticals Corporation [ADMP] has a Total Debt to Total Equity ratio set at 11.32. Additionally, ADMP Total Debt to Total Capital is recorded at 10.17, with Total Debt to Total Assets ending up at 8.28. Long-Term Debt to Equity for the company is recorded at 4.11, with the Long-Term Debt to Total Capital now at 3.69.
Reflecting on the efficiency of the workforce at the company, Adamis Pharmaceuticals Corporation [ADMP] managed to generate an average of -$171,385 per employee. Receivables Turnover for the company is 14.58 with a Total Asset Turnover recorded at a value of 0.41.Adamis Pharmaceuticals Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.30.
Earnings per share (EPS) analysis for Adamis Pharmaceuticals Corporation [ADMP] stock
With the latest financial reports released by the company, Adamis Pharmaceuticals Corporation posted -0.08/share EPS, while the average EPS was predicted by analysts to be reported at -0.04/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -100.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ADMP.
Adamis Pharmaceuticals Corporation [ADMP]: Insider Ownership positions
There are presently around $5 million, or 7.10% of ADMP stock, in the hands of institutional investors. The top three institutional holders of ADMP stocks are: VANGUARD GROUP INC with ownership of 1,953,423, which is approximately 2.836% of the company’s market cap and around 1.30% of the total institutional ownership; BLACKROCK INC., holding 1,333,297 shares of the stock with an approximate value of $0.94 million in ADMP stocks shares; and MAVEN SECURITIES LTD, currently with $0.71 million in ADMP stock with ownership of nearly New of the company’s market capitalization.
Positions in Adamis Pharmaceuticals Corporation stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 18 institutional holders increased their position in Adamis Pharmaceuticals Corporation [NASDAQ:ADMP] by around 2,046,496 shares. Additionally, 22 investors decreased positions by around 520,136 shares, while 19 investors held positions by with 4,067,732 shares. The mentioned changes placed institutional holdings at 6,634,364 shares, according to the latest SEC report filing. ADMP stock had 11 new institutional investments in for a total of 1,297,685 shares, while 11 institutional investors sold positions of 200,183 shares during the same period.